Is attention-deficit/hyperactivity disorder (ADHD) due to a delay in brain development or the result of complete deviation from typical development? In the current issue of Biological Psychiatry, Dr. Philip Shaw and colleagues present evidence for delay based on a study by the National Institutes of Health.
As many as 5% to 7% of elementary school children are diagnosed with Attention Deficit Hyperactivity Disorder (ADHD), a behavioral disorder that causes problems with inattentiveness, over-activity, impulsivity, or a combination of these traits. Many of these children are treated with psychostimulant drugs, and while doctors and scientists know a lot about how these drugs work and their effectiveness, little is known about their long-term effects.
In the first study of its kind, researchers at Queens College and Mount Sinai School of Medicine have found that low socioeconomic status (SES) and maternal gestational diabetes together may cause a 14-fold increased risk of attention deficit hyperactivity disorder (ADHD) in six year olds. The data are published in the January issue of theArchives of Pediatrics and Adolescent Medicine, one of the JAMA/Archives journals.
Although there have been cardiovascular safety concerns about attention-deficit/hyperactivity disorder (ADHD) medications because of their ability to increase heart rate and blood pressure levels, an analysis that included more than 150,000 ADHD users found no evidence of an increased risk of heart attack, stroke, or sudden cardiac death associated with current use compared with non-use or rare-use among young and middle-aged adults, according to a study appearing in JAMA. The study is being released early online because of its public health importance. Included in this report is a video summary of the study results.
Pediatric researchers analyzing genetic influences in attention-deficit/hyperactivity disorder (ADHD) have found alterations in specific genes involved in important brain signaling pathways. The study raises the possibility that drugs acting on those pathways might offer a new treatment option for patients with ADHD who have those gene variants – potentially, half a million U.S. children.
A study of more than 400 children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) has found a link between the children’s routine play settings and the severity of their symptoms, researchers report. Those who regularly play in outdoor settings with lots of green (grass and trees, for example) have milder ADHD symptoms than those who play indoors or in built outdoor environments, the researchers found. The association holds even when the researchers controlled for income and other variables. Included in this report is a link to download a free copy of the full text, original study.
Attention Deficit Hyperactivity Disorder (ADHD) medications do not increase the risk for heart disease or heart attack in children and young adults, according to a Vanderbilt study of 1.2 million patients taking drugs including Ritalin, Adderall, Concerta, and Strattera between 1998 and 2005. The study, published online today by the New England Journal of Medicine (NEJM) and authored by William Cooper, M.D., MPH, a Vanderbilt Professor of Pediatrics and Preventive Medicine, is the largest ever to examine potential risks posed by drugs to treat ADHD.
Updated guidelines from the American Academy of Pediatrics (AAP) offer new information on diagnosing and treating Attention-Deficit/Hyperactivity Disorder (ADHD) in younger children and in adolescents. Emerging evidence makes it possible to diagnose and manage ADHD in children from ages 4 to 18 (the previous AAP guidelines, from 2000 and 2001, covered children ages 6 to 12).
Recent Comments